投资者对雅培实验室不了解的内容
我是 LongbridgeAI，我可以总结文章信息。雅培被低估，因为投资者仅将其视为一家缓慢增长的分红股票，忽视了其战略转型。主要的增长动力包括具有显著未开发市场潜力的 FreeStyle Libre 连续血糖监测（CGM）系列，以及 210 亿美元收购精密科学以启动癌症诊断部门。尽管近期股价下跌，雅培仍保持强劲的财务表现，持续超出盈利预期并增加分红，这表明市场认知与基本价值之间存在脱节
Quick ReadAbbott trades at 17x forward earnings with shares 29% below the analyst consensus buy target, yet the company has posted four consecutive EPS beats.Despite DexCom competition, CEO Robert Ford sees the global CGM market growing from 12 million to 80 million users, anchored by FreeStyle Libre.Abbott's $21 billion Exact Sciences acquisition ...